Eli Lilly & financials
$1,184.63−0.01%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.97B | $19.80B | $19.29B | $17.60B | $15.56B | $12.73B | $13.53B | $11.44B | $11.30B | $8.77B | $9.35B | $9.50B |
| Gross profit | $19.71B | $16.22B | $15.92B | $14.59B | $13.11B | $10.50B | $11.13B | $9.27B | $9.13B | $7.09B | $7.57B | $7.64B |
| Gross margin | 85.8% | 81.9% | 82.5% | 82.9% | 84.3% | 82.5% | 82.2% | 81.0% | 80.8% | 80.9% | 80.9% | 80.4% |
| Operating income | $8.98B | $8.91B | $8.37B | $7.37B | $6.87B | $3.69B | $5.15B | $1.53B | $3.71B | $2.51B | $2.39B | $450.4M |
| Net income | $7.09B | $7.40B | $6.64B | $5.58B | $5.66B | $2.76B | $4.41B | $970.3M | $2.97B | $2.24B | $2.19B | -$57.4M |
| Net margin | 30.9% | 37.4% | 34.4% | 31.7% | 36.4% | 21.7% | 32.6% | 8.5% | 26.3% | 25.6% | 23.4% | −0.6% |
| Diluted EPS | $7.94 | $8.26 | $7.39 | $6.21 | $6.29 | $3.06 | $4.88 | $1.07 | $3.28 | $2.48 | $2.41 | $-0.06 |
| EBITDA | $12.99B | $10.29B | $9.57B | $8.86B | $7.50B | $5.76B | $6.17B | $4.90B | $4.72B | $3.02B | $3.08B | $3.84B |
| Operating cash flow | $10.69B | $5.33B | $3.22B | $8.84B | $3.09B | $1.67B | $2.47B | $3.71B | $1.47B | $1.17B | -$892.4M | -$841.4M |
| Free cash flow | $7.76B | $3.01B | $677.9M | $6.75B | $1.39B | $156.0M | $977.7M | $2.36B | $241.4M | $179.7M | -$1.96B | -$1.81B |
| Diluted shares | 893.7M | 895.9M | 898.0M | 898.8M | 899.8M | 900.6M | 903.4M | 905.0M | 904.2M | 903.8M | 907.4M | 899.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.95B | $5.28B | $7.27B | $9.79B | $3.38B | $3.09B |
| Short-term investments | $0.00 | $0.00 | $0.00 | $121.6M | $170.1M | $127.4M |
| Total debt | $54.91B | $43.37B | $42.50B | $42.51B | $39.90B | $38.52B |
| Total assets | $142.28B | $116.58B | $112.48B | $114.94B | $100.92B | $89.39B |
| Total liabilities | $108.40B | $85.38B | $85.94B | $91.08B | $82.57B | $73.54B |
| Shareholders' equity | $33.88B | $31.20B | $26.54B | $23.85B | $18.35B | $15.85B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology